BANK VONTOBEL/PUT/NOVO NORDISK ADR B/110/0.1/20.12.24 | Market Closed - Boerse Frankfurt Warrants 19:01:37 05/07/2024 BST | ||
| 0.2 EUR | -13.42% |
|
| Current month | +21.95% | ||
| 1 month | -2.44% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 05/07/24 | 0.2 | -13.42% |
| 04/07/24 | 0.231 | -11.15% |
| 03/07/24 | 0.26 | +42.86% |
| 02/07/24 | 0.182 | +30.00% |
| 01/07/24 | 0.14 | -14.63% |
Real-time Boerse Frankfurt Warrants
Last update July 05, 2024 at 07:01 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM8D3H |
| ISIN | DE000VM8D3H3 |
| Date issued | 11/01/2024 |
| Strike | 110 $ |
| Maturity | 20/12/2024 (167 Days) |
| Parity | 10 : 1 |
| Emission price | 1.12 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.33 € |
|---|---|
| Lowest since issue | 0.14 € |
| Spread | 0.01 € |
| Spread % | 4.81% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974
DKK
Average target price
952.2
DKK
Spread / Average Target
-2.24%
- Stock Market
- Warrants
- Warrant
